Lu Yan, Xing Fei, Peng Songlin
the Department of Hospital Infection Control and Public Health Management, the Seventh Affiliated Hospital, Sun Yat-sen University, No. 628 Zhenyuan Road, Guangming District, Shenzhen, 518107, China.
the Department of Oncology, the Shengjing Hospital of China Medical University, Shenyang, No. 36 Sanhao Street, Heping District, 110004, China.
Heliyon. 2024 May 7;10(9):e30782. doi: 10.1016/j.heliyon.2024.e30782. eCollection 2024 May 15.
The CXCL12-CXCR4/CXCR7 axis is garnering growing attention. But the comprehension of its function in the progression of HCC remains controversial. The purpose of this study was to investigate the effects of CXCL12 and its receptor on the prognosis of patients with viral hepatitis-associated HCC after hepatectomy.
A total of 86 patients had been enrolled who had undergone hepatectomy for HCC and followed up to July 31, 2019, and their clinicopathological and follow-up data were recorded. Tumor and peritumoral tissues were obtained to detect the expression of CXCL12, CXCR4, and CXCR7 using immunohistochemistry. Real-time polymerase chain reaction was utilized to detect hepatitis B or C virus loads, while survival analysis was performed using the Kaplan-Meier method. Furthermore, the Cox proportional hazards regression model was employed to analyze the factors affecting the prognosis.
The results revealed that the CXCL12, CXCR4, and CXCR7 expression in tumor tissues was lower than in the corresponding non-tumor tissues in 20.93 %, 22.09 %, and 23.26 % of the patients, respectively, and that only CXCL12 was found to be related to the extrahepatic invasion of HCC. The survival analysis and Cox regression showed that only CXCL12 was associated with the postoperative survival of patients with HCC, and that it was an independent prognostic risk factor in the CXCL12-CXCR4/CXCR7 axis. The CXCL12 group represented shorter progression-free survival and lower overall survival rates. However, the subgroup analysis displayed that the survival difference associated with CXCL12 was only manifested in patients with higher expression of CXCR4 or CXCR7 in HCC, as compared to the surrounding tissues.
Our findings suggest that, when assessing the prognostic significance of CXCL12 in HCC, it is essential to consider the expression level of its receptor. Nevertheless, CXCL12 can potentially serve as a promising prognostic marker for HCC.
CXCL12 - CXCR4/CXCR7轴正受到越来越多的关注。但其在肝癌进展中的功能理解仍存在争议。本研究旨在探讨CXCL12及其受体对病毒性肝炎相关肝癌患者肝切除术后预后的影响。
共纳入86例行肝癌肝切除术的患者,随访至2019年7月31日,记录其临床病理及随访数据。获取肿瘤及瘤旁组织,采用免疫组织化学法检测CXCL12、CXCR4和CXCR7的表达。利用实时聚合酶链反应检测乙型或丙型肝炎病毒载量,采用Kaplan - Meier法进行生存分析。此外,采用Cox比例风险回归模型分析影响预后的因素。
结果显示,分别有20.93%、22.09%和23.26%的患者肿瘤组织中CXCL12、CXCR4和CXCR7的表达低于相应的非肿瘤组织,且仅发现CXCL12与肝癌的肝外侵犯有关。生存分析和Cox回归显示,仅CXCL12与肝癌患者术后生存相关,且是CXCL12 - CXCR4/CXCR7轴中的独立预后危险因素。CXCL12组的无进展生存期较短,总生存率较低。然而,亚组分析显示,与CXCL12相关的生存差异仅在肝癌中CXCR4或CXCR7表达高于周围组织的患者中表现出来。
我们的研究结果表明,在评估CXCL12在肝癌中的预后意义时,必须考虑其受体的表达水平。尽管如此,CXCL12有可能成为肝癌有前景的预后标志物。